| # | Title | Journal | Year | Citations |
|---|
| 1 | Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial | Lancet, The | 2018 | 396 |
| 2 | Janus kinase inhibitors in autoimmune diseases | Annals of the Rheumatic Diseases | 2013 | 350 |
| 3 | Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system | Annals of the Rheumatic Diseases | 2006 | 282 |
| 4 | Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study | Annals of the Rheumatic Diseases | 2010 | 251 |
| 5 | Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions | Annals of the Rheumatic Diseases | 2016 | 232 |
| 6 | A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea | Annals of the Rheumatic Diseases | 2018 | 196 |
| 7 | Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach | Nature Reviews Rheumatology | 2022 | 193 |
| 8 | Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study | Annals of the Rheumatic Diseases | 2016 | 191 |
| 9 | JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial | Nephrology Dialysis Transplantation | 2018 | 183 |
| 10 | Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFκB p65 protein expression | Oncogene | 1997 | 165 |
| 11 | The changing landscape of biosimilars in rheumatology | Annals of the Rheumatic Diseases | 2016 | 160 |
| 12 | Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study | Annals of the Rheumatic Diseases | 2015 | 149 |
| 13 | The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells | Annals of the Rheumatic Diseases | 2014 | 136 |
| 14 | Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: Preventive and therapeutic effects on experimental autoimmune encephalomyelitis | Biochemical and Biophysical Research Communications | 2008 | 131 |
| 15 | Tocilizumab in patients with adult-onset still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial | Annals of the Rheumatic Diseases | 2018 | 129 |
| 16 | Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study | Annals of the Rheumatic Diseases | 2016 | 125 |
| 17 | Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR) | Cardiovascular Diabetology | 2020 | 121 |
| 18 | Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study | Arthritis Research and Therapy | 2016 | 117 |
| 19 | Dopamine Induces IL-6–Dependent IL-17 Production via D1-Like Receptor on CD4 Naive T Cells and D1-Like Receptor Antagonist SCH-23390 Inhibits Cartilage Destruction in a Human Rheumatoid Arthritis/SCID Mouse Chimera Model | Journal of Immunology | 2011 | 115 |
| 20 | Interleukin-4 as a potent inhibitor of bone resorption | Biochemical and Biophysical Research Communications | 1990 | 110 |
| 21 | Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study | Modern Rheumatology | 2015 | 109 |
| 22 | Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study | Modern Rheumatology | 2014 | 105 |
| 23 | Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study | Annals of the Rheumatic Diseases | 2012 | 102 |
| 24 | Osteoblasts are regulated by the cellular adhesion through ICAM-1 and VCAM-1 | Journal of Bone and Mineral Research | 1995 | 97 |
| 25 | Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis | Rheumatology | 2019 | 92 |
| 26 | Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis | Annals of the Rheumatic Diseases | 2007 | 89 |
| 27 | Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System | Frontiers in Immunology | 2018 | 89 |
| 28 | State‐of‐the‐art treatment of systemic lupus erythematosus | International Journal of Rheumatic Diseases | 2020 | 85 |
| 29 | IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab | Annals of the Rheumatic Diseases | 2014 | 84 |
| 30 | Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study | Annals of the Rheumatic Diseases | 2014 | 82 |
| 31 | Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study) | Annals of the Rheumatic Diseases | 2016 | 81 |
| 32 | Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study | Rheumatology | 2020 | 81 |
| 33 | Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus | Arthritis and Rheumatism | 2005 | 80 |
| 34 | Fast track algorithm: How to differentiate a “scleroderma pattern” from a “non-scleroderma pattern” | Autoimmunity Reviews | 2019 | 79 |
| 35 | Constitutive Chemokine Production Results in Activation of Leukocyte Function-Associated Antigen-1 on Adult T-Cell Leukemia Cells | Blood | 1998 | 75 |
| 36 | Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis | Modern Rheumatology | 2009 | 75 |
| 37 | Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis | Rheumatology | 2018 | 70 |
| 38 | Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet’s disease | Modern Rheumatology | 2011 | 69 |
| 39 | Current concepts in the management of rheumatoid arthritis | Korean Journal of Internal Medicine | 2016 | 67 |
| 40 | Hepatocyte growth factor enhances adhesion of breast cancer cells to endothelial cells in vitro through up-regulation of CD44 | Experimental Cell Research | 2003 | 66 |
| 41 | In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis | Annals of the Rheumatic Diseases | 2012 | 66 |
| 42 | Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition | Clinical Immunology | 2018 | 66 |
| 43 | Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study) | Modern Rheumatology | 2011 | 65 |
| 44 | IL-6 and sIL-6R induces STAT3-dependent differentiation of human VSMCs into osteoblast-like cells through JMJD2B-mediated histone demethylation of RUNX2 | Bone | 2019 | 65 |
| 45 | Monocyte chemoattractant protein-1 enhances expression of intercellular adhesion molecule-1 following ischemia-reperfusion of the liver in rats | Hepatology | 1998 | 64 |
| 46 | Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside | Journal of Biochemistry | 2015 | 63 |
| 47 | Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system | Current Opinion in Pharmacology | 2018 | 63 |
| 48 | A multicenter phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease | Modern Rheumatology | 2017 | 62 |
| 49 | Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2) | Modern Rheumatology | 2008 | 61 |
| 50 | Phenotypic Changes of Lymphocytes in Patients with Systemic Lupus Erythematosus Who Are in Longterm Remission After B Cell Depletion Therapy with Rituximab | Journal of Rheumatology | 2011 | 60 |
